MDMB-BINACA

The following information was compiled in June 2023 and is subject to change as new research is conducted and as new information becomes available:

Description: MDMB-BINACA (also referred to as MDMB-BUTINACA) is a novel synthetic cannabinoid with structural similarity to MDMB-PINACA, 4F-MDMB-BINACA, ADB-BINACA (ADB-BUTINACA) and other synthetic cannabinoids. MDMB-BINACA was first detected in April 2023 by our laboratory in the United States in a blood sample submitted from the United Kingdom.

Sample Source: Toxicology case – United Kingdom.

Sample Appearance: Toxicology specimen – blood.

Pharmacology: The activity and potency of MDMB-BINACA are unknown. Based on structural similarity, MDMB-BINACA is expected to have similar effects to other biologically active synthetic cannabinoids.

Toxicology: MDMB-BINACA has been detected in one toxicology case at the CFSRE.

Drug Materials: MDMB-BINACA has not been identified in drug materials at the CFSRE to date. Reports from partnering laboratories indicate that MDMB-BINACA has been detected in samples collected in the United States.

Demographics / Geographics: Limited information is available at this time; however, communications with colleagues indicate that MDMB-BINACA has been identified in North America, Europe, and Asia.

Legal Status: MDMB-BINACA is not explicitly scheduled in the United States. MDMB-BINACA is within the scope of the national class-wide synthetic cannabinoid scheduling action imposed by China in July 2021.

Class:

Cannabinoid

Appearance:

Blood

Formula:

C19H27N3O3

MW:

345.43

[M+]:

345

[M+H]+:

346.2125

IUPAC:

methyl 2-[(1-butylindazole-3-carbonyl)amino]-3,3-dimethyl-butanoate

Report Date:

June 27, 2023